Avinash Poojari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avinash Poojari has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Ajeet Kumar Gandhi
Radiation Oncology Dr Ram Manohar Lohia Institute of Medical Sciences
1 shared publication- Ajeet Kumar Gandhi
Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
1 shared publication Anoop Srivastava
Radiation Oncology Dr Ram Manohar Lohia Institute of Medical Sciences
1 shared publicationAvinav Bharati
Radiation Oncology Dr Ram Manohar Lohia Institute of Medical Sciences
1 shared publicationBhanu Vashistha
Department of Radiation Oncology, Christian Medical College and Hospital, Ludhiana, Punjab, India
1 shared publicationMadhup Rastogi
Radiation Oncology Dr Ram Manohar Lohia Institute of Medical Sciences
1 shared publication
Latest Publications
- 4 August 2023
- Published by Elsevier
- p. 323-325
Crossover study
- Open Access
- 25 June 2023
- Published by Wiley in Precision Radiation Oncology
- Vol. 7 (2) , 118-127
Whole‐breast irradiation with lumpectomy cavity boost and regional nodal irradiation: Dosimetric comparison of 3D‐CRT using sequential boost and dual partial‐arc VMAT using simultaneous integrated boost
To compare volumetric modulated arc therapy (VMAT) with simultaneous tumor bed boost (dpSIB‐VMAT) to the whole breast and regional nodal irradiation (RNI) against standard three‐dimensional conformal radiotherapy plus RNI with sequential tumor bed boost (3D‐CRT‐seqB). Thirty patients who underwent breast cancer surgery (BCS) with axillary lymph node dissection (ALND) were enrolled. Two plans were generated for each case: (1) dpSIB‐VMAT, and (2) 3D‐CRT‐seqB plans. Planning target volume (PTV)‐Breast and PTV‐Nodes were prescribed at a dose of 50 Gy in 25 fractions in both plans. PTV‐Boost was prescribed at a dose of 60 Gy in 25 fractions simultaneously in the dpSIB‐VMAT plans, whereas it was planned sequentially in the 3D‐CRT‐seqB plans at 10 Gy in 5 fractions. Dosimetric parameters were compared between the two plans. Both plans achieved the target coverage. Dmean of the heart was lower with dpSIB‐VMAT in left‐sided cases (7.17 ± 0.66 Gy vs. 10.12 ± 2.91 Gy; t = 4.02; p = 0.001). Ipsilateral mean lung dose (15.87 ± 1.40 Gy vs. 19.82 ± 3.20 Gy; t = 6.30; p<0.001) was significantly lower but mean doses of the contralateral breast (4.30 ± 1.76 Gy vs. 1.48 ± 0.76 Gy; t = ‐7.84; p<0.001), contralateral lung (3.86 ± 1.21 Gy vs. 0.96 ± 0.25 Gy; t = ‐13.13; p<0.001) and esophagus (13.11 ± 2.63 Gy vs. 10.32 ± 3.56 Gy; t = ‐6.65; p<0.001) were relatively higher with dpSIB‐VMAT. Dosimetrically, dpSIB‐VMAT reduced doses to the ipsilateral lung and heart (in left breast but not right breast cases) compared to 3D‐CRT‐seqB plans for adequate target coverage.
- 25 June 2023
- Published by Wiley in Precision Radiation Oncology
- Vol. 7 (2) , 118-127
Open AccessWhole‐breast irradiation with lumpectomy cavity boost and regional nodal irradiation: Dosimetric comparison of 3D‐CRT using sequential boost and dual partial‐arc VMAT using simultaneous integrated boost
To compare volumetric modulated arc therapy (VMAT) with simultaneous tumor bed boost (dpSIB‐VMAT) to the whole breast and regional nodal irradiation (RNI) against standard three‐dimensional conformal radiotherapy plus RNI with sequential tumor bed boost (3D‐CRT‐seqB). Thirty patients who underwent breast cancer surgery (BCS) with axillary lymph node dissection (ALND) were enrolled. Two plans were generated for each case: (1) dpSIB‐VMAT, and (2) 3D‐CRT‐seqB plans. Planning target volume (PTV)‐Breast and PTV‐Nodes were prescribed at a dose of 50 Gy in 25 fractions in both plans. PTV‐Boost was prescribed at a dose of 60 Gy in 25 fractions simultaneously in the dpSIB‐VMAT plans, whereas it was planned sequentially in the 3D‐CRT‐seqB plans at 10 Gy in 5 fractions. Dosimetric parameters were compared between the two plans. Both plans achieved the target coverage. Dmean of the heart was lower with dpSIB‐VMAT in left‐sided cases (7.17 ± 0.66 Gy vs. 10.12 ± 2.91 Gy; t = 4.02; p = 0.001). Ipsilateral mean lung dose (15.87 ± 1.40 Gy vs. 19.82 ± 3.20 Gy; t = 6.30; p<0.001) was significantly lower but mean doses of the contralateral breast (4.30 ± 1.76 Gy vs. 1.48 ± 0.76 Gy; t = ‐7.84; p<0.001), contralateral lung (3.86 ± 1.21 Gy vs. 0.96 ± 0.25 Gy; t = ‐13.13; p<0.001) and esophagus (13.11 ± 2.63 Gy vs. 10.32 ± 3.56 Gy; t = ‐6.65; p<0.001) were relatively higher with dpSIB‐VMAT. Dosimetrically, dpSIB‐VMAT reduced doses to the ipsilateral lung and heart (in left breast but not right breast cases) compared to 3D‐CRT‐seqB plans for adequate target coverage.